⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8487795 | 0.67 | — | — | |
| SCHEMBL4723513 | 0.65 | — | — | |
| SCHEMBL16703925 | 0.65 | — | — | |
| SCHEMBL4721251 | 0.63 | — | — | |
| SCHEMBL20642830 | 0.59 | — | — | |
| SCHEMBL19823150 | 0.59 | — | — | |
| SCHEMBL24662259 | 0.58 | — | — | |
| SCHEMBL4764211 | 0.58 | — | — | |
| SCHEMBL10015535 | 0.58 | — | — | |
| SCHEMBL24662260 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999791-B2 | Prevention of disulfide bond reduction during recombinant production of polypeptides | GENENTECH, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-11987637-B1 | Prevention of disulfide bond reduction during recombinant production of polypeptides | GENENTECH, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-11976127-B1 | Prevention of disulfide bond reduction during recombinant production of polypeptides | GENENTECH, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240132612-A1 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | GENENTECH, INC. (US) | 2024-04-25 | — | — | US | disclosed |
| US-20230365704-A1 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | GENENTECH, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11639395-B2 | Prevention of disulfide bond reduction during recombinant production of polypeptides | GENENTECH, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11078294-B2 | Prevention of disulfide bond reduction during recombinant production of polypeptides | GENENTECH, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20210188993-A1 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | GENENTECH, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210095040-A1 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | GENENTECH, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-10906986-B2 | Prevention of disulfide bond reduction during recombinant production of polypeptides | GENENTECH, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-8574869-B2 | Prevention of disulfide bond reduction during recombinant production of polypeptides | GENENTECH, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| CN-101421282-B | Treatment of hyperproliferative diseases with vinca alkaloid N-oxides and analogs | STAT OF OREGON ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNI | 2013-08-14 | — | — | CN | disclosed |
| US-20130017598-A1 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | GENENTECH, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| CN-102574866-A | Camptothecin derivatives | THRESHOLD PHARMACEUTICALS INC | 2012-07-11 | — | — | CN | disclosed |
| CN-102161679-A | Compositions and methods for treating cancer | THRESHOLD PHARMACEUTICALS INC | 2011-08-24 | — | — | CN | disclosed |
| CN-101932591-A | Prevention of disulfide bond reduction during recombinant production of polypeptides | GENENTECH INC | 2010-12-29 | — | — | CN | disclosed |
| US-20090053786-A1 | Prevention of disulfide bond reduction during recombinant production of polypeptides | GENENTECH, INC. | 2009-02-26 | — | — | US | disclosed |
| EP-1689436-A1 | TREATMENT OF RHEUMATOID ARTHRITIS WITH HYPOXIA-INDUCIBLE FACTOR a ANTAGONISTS | Entelos, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050148496-A1 | Treatment of rheumatoid arthritis with hypoxia inducible factor-1alpha antagonists | ENTELOS, INC. (US) | 2005-07-07 | — | — | US | disclosed |
| WO-2005053744-A1 | TREATMENT OF RHEUMATOID ARTHRITIS WITH HYPOXIA-INDUCIBLE FACTOR 1α ANTAGONISTS | ENTELOS, INC. (US) | 2005-06-16 | — | — | WO | disclosed |